First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $75, Implies 62% Upside

First Tracks Biotherapeutics, Inc. stock's average price target increased to $75 from $74.17 by 12 analysts, with a range of $57 to $110. This implies a 62% upside from the Nov. 3 closing price. All 12 analysts maintain a 'Buy' rating.

Original reporting
Published Nov 4, 2026, 10:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 10:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
First Tracks Biotherapeutics, Inc. Stock 12‑Month Price Target Raised to $75, Implies 62% Upside — source image
Decision brief

The 30-second read

Low
01

Market read

Analyst price target update for a micro‑cap biotech; limited immediate trading impact.

02

Timing

post-market today

Relevance 6/10Novelty 5/10Timing: post-market today

Background

Analyst consensus price target for First Tracks Biotherapeutics, Inc. raised to $75, implying ~62% upside.

Market effects

none

none

none

Related articles

$TRAXHighAI 8/10

First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

First Tracks Biotherapeutics, Inc. (TRAX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 First Tracks Biotherapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update • Announced ANB033 achieved a statistically significant and clinically meaningful protective effect on both gluten-induced intestinal damage and symptoms in Cohort

$TRAXMedAI 8/10

First Tracks Biotherapeutics (TRAX) Reports Positive ANB033 Celiac Cohort Results

First Tracks Biotherapeutics (TRAX) reported positive Phase 1b trial results for ANB033 in celiac disease, showing significant protection against gluten-induced damage. The company expects mucosal-healing data in Q1 2027 and eosinophilic esophagitis results in Q3 2027. It also anticipates late-stage trials for celiac disease and Phase 2 trials for vitiligo in 2027. The company raised $200 million in a private placement, bringing pro forma cash to $343 million.